A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

NCT01366638 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: TMC435
DRUG: Peginterferon alfa-2b (pegIFN alfa-2b)
DRUG: Ribavirin (RBV)

Sponsor

Janssen Pharmaceutical K.K.